PFE

Pfizer Inc.

Fundamental data last updated:May 19, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - General

Exchange

NYSE

County of HQ

US

Next Earnings Date

08/04/2026

Business Summary

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

 


VALUATION

P/E

19.26

Market Cap ($M USD)

$144.51B

Forward P/E

10.65

PEG

0.13

PRICE TO SALES

2.28

PRICE TO BOOK

1.60

EV / EBITDA

12.23

5-Year Average P/E

Free Cash Flow Yield

6.56%

DCF Value

$40.24

Graham Number

$21.65

Price to FCF

15.24

EV to FCF

21.85

Earnings Yield

5.19%

FCF Yield

6.56%

DIVIDEND

Yield

6.78%

Annual Payout

$1.72

Payout Ratio

130.54%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.32

Next Year EPS Growth Estimate

$2.38

Next Year Revenue Growth Estimate

$5.34T

Return on Equity (ROE)

8.37%

FREE CASH FLOW

Operating Margin

23.45%

Debt-to-Equity

0.78

Piotroski F-Score

5

Altman Z-Score

2.07

Return on Invested Capital (ROIC)

8.57%

Current Ratio

1.25

Quick Ratio

0.94

Net Debt to EBITDA

3.70

Interest Coverage

5.53

Gross Profit margin

69.35%

FCF PER SHARE

$1.67

REVENUE PER SHARE

$11.13

Gainseekers Quantitative Analysis

Summary

Pfizer Inc. presents a compelling valuation discrepancy. Recent pricing indicated it traded significantly below its DCF value of $41.50 and its Graham Number of $21.65, suggesting a potential undervaluation. The Forward P/E of 10.76 and a PEG ratio of 0.13 highlight growth at a reasonable price, while the Altman Z-score of 2.06 suggests moderate financial stability. However, the earnings yield of 5.13% and a high payout ratio of 130.54% raise questions about sustainable dividend payments. Overall, the market may be underestimating Pfizer’s intrinsic value.

AI Exposure / Tech Reliance

In the healthcare sector, Pfizer is well-positioned to leverage AI and tech advancements, particularly in drug discovery and personalized medicine. The industry's shift towards digital health solutions aligns with Pfizer's capabilities to innovate and adapt. This resilience ensures they remain competitive amidst technological disruptions.

The Bull Case

For the value-driven investor, Pfizer's ROIC of 8.57% and a solid operating margin of 23.45% underscore efficient capital use and strong pricing power. The Piotroski F-Score of 5 indicates moderate financial health, while a TTM yield of 6.70% offers attractive income potential. Despite a modest FCF yield of 6.48%, the company's ability to generate cash flow supports its long-term growth narrative.

The Bear Case

Yet, structural risks loom large. The Price/Book ratio of 1.62 and Price/Sales of 2.31 suggest the stock isn't a bargain on a relative basis. The net debt to EBITDA ratio of 3.70 signals leverage concerns, compounded by an interest coverage ratio of 5.53, which may strain financial flexibility. Additionally, trading near its 52-week high, the stock could face technical resistance, challenging further upside.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$27.60

Institutional Ownership %

1-Year Beta

0.31

Insider Buying % (6 Mo)

Distance to 52-Week High

13.39%

Distance to 52-Week Low

11.46%

EARNINGS SURPRISE %

3.88%

50-DAY SMA

$26.96

200-DAY SMA

$25.75

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.